(Source: Eli Lilly and Company) INDIANAPOLIS, Nov. 4, 2015/PRNewswire / -- Eli Lilly and Company (NYSE: LLY) announces that detailed data for two phase 3 pivotal trials of the investigational medicine baricitinib in rheumatoid arthritis, RA-BEGIN and RA-BEAM, will be presented at the American College of Rheumatology/Association of Rheumatology Health Professionals annual meeting in San Francisco, November 6-11, 2015. Detailed results from a phase 3 study of ixekizumab in psoriatic arthritis will also be presented at the conference. 'Lilly is committed to raising expectations for people living with some of the world's most debilitating chronic conditions, including rheumatoid arthritis and...
↧